-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VpQvIl3z/Kih1XoB2pRccPiqEHHTmTF1K3phgMkswkb6WdQl5uFaiSd3qtV6bc5o
 pkvZ+JBzX/hxSI21nFsdKA==

<SEC-DOCUMENT>0000950123-10-051193.txt : 20100708
<SEC-HEADER>0000950123-10-051193.hdr.sgml : 20100708
<ACCEPTANCE-DATETIME>20100519143940
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-10-051193
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20100519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>Correspondence</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" align="left">M<FONT style="font-variant: small-caps">intz</FONT> L<FONT style="font-variant: small-caps">evin</FONT><BR>
Joel I. Papernik  |   212 692 6774   |   jipapernik@mintz.com</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Chrysler Center<BR>
666 Third Avenue<BR>
New York, NY 10017<BR>
212-935-3000<BR>
212-983-3115 fax<BR>
www.mintz.com</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">May&nbsp;19, 2010
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U><B>CORRESPONDENCE FILED</B></U><BR>
<U><B>VIA EDGAR TRANSMISSION</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Securities and Exchange Commission<BR>
Division of Corporation Finance<BR>
100 F Street, N.W.<BR>
Mail Stop 4720<BR>
Washington, D.C. 20549

</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Re:</TD>
    <TD>&nbsp;</TD>
    <TD><B>Cyclacel Pharmaceuticals, Inc.<BR>
Current Report on Form&nbsp;8-K<BR>
Filed on May&nbsp;13, 2010<BR>
File No.&nbsp;000-50626<BR></B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Ladies and Gentlemen:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On behalf of Cyclacel Pharmaceuticals, Inc. (the <B>&#147;Company&#148;</B>), we hereby respond to the letter
sent by the Securities and Exchange Commission (the <B>&#147;Commission&#148;</B>) dated May&nbsp;14, 2010 from Tabitha
Akins, Staff Accountant, Division of Corporate Finance (the &#147;<B>Comment Letter</B>&#148;) regarding the
Company&#146;s Current Report on Form 8-K filed with the Commission on May&nbsp;13, 2010 (the &#147;<B>Form&nbsp;8-K</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Set forth below are the Company&#146;s responses to the Commission&#146;s Comment Letter. The Company&#146;s
responses are numbered to correspond to the comments, as set forth in the Comment Letter, which,
for convenience, we have incorporated into this response letter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or
Completed Interim Review.</B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Please revise your disclosure to elaborate on any internal control deficiencies
that allowed the error in calculating the net loss per share and in the errors related to
the presentation and Preferred Stock dividend to prevail over time and explain whether
these amounted to a material weakness</U>.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Response: </I>The Company
acknowledges the Commission&#146;s comment. However, on May&nbsp;17, 2010, the Company filed
Amendment No.&nbsp;1 to its Annual Report on Form 10-K for
the year ended December&nbsp;31, 2009 (the &#147;<B>Form&nbsp;10-K/A</B>,&#148; which was again
amended on May&nbsp;19, 2010 to correct the date of the report of the Company&#146;s auditor) and, as explained in the &#147;<I>Explanatory Note</I>&#148; to
the Form 10-K/A, in addition to identifying the error in the Company&#146;s calculation and disclosures
in the consolidated statements of cash flows related to the payment of preferred dividends, the
Company&#146;s management in parallel identified a related deficiency with respect to its internal
controls over financial reporting, specifically in its controls over the computation of net loss
per share and the financial statement presentation of its preferred stock dividends in the
statement of cash flows, that constitutes a material weakness. As a result, the Company has
amended Part&nbsp;I, Item&nbsp;9T, of the Form 10-K/A, captioned &#147;<I>Controls and Procedures</I>,&#148; under which
item management revised its previous assessment of its internal
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt">N<FONT style="font-variant: small-caps">ew</FONT> Y<FONT style="font-variant: small-caps">ork</FONT> | W<FONT style="font-variant: small-caps">ashington</FONT> | B<FONT style="font-variant: small-caps">oston</FONT> | S<FONT style="font-variant: small-caps">tamford</FONT> | L<FONT style="font-variant: small-caps">os</FONT> A<FONT style="font-variant: small-caps">ngeles</FONT> | P<FONT style="font-variant: small-caps">alo</FONT> A<FONT style="font-variant: small-caps">lto</FONT> | S<FONT style="font-variant: small-caps">an</FONT> D<FONT style="font-variant: small-caps">iego</FONT> | L<FONT style="font-variant: small-caps">ondon</FONT>

</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">May&nbsp;17, 2010<BR>
Page 2

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">controls,
described the deficiency that constituted a material weakness, and concluded that its
internal controls over financial reporting were deficient as of December&nbsp;31, 2009 (see page 90 of
the Form 10-K/A). Corresponding changes were also made under Part&nbsp;I, Item&nbsp;1A, captioned &#147;<I>Risk
Factors&#151;Failure to achieve and maintain internal controls in accordance with Sections&nbsp;302 and 404
of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock
price&#148; </I>and &#147;<I>We incur increased costs and management resources as a result of being a public
company, and we still may fail to comply with public company
obligations,&#148; </I>(see page 17 of the Form
10-K/A); Part&nbsp;II, Item&nbsp;6, captioned &#147;<I>Selected Financial Data&#148; </I>(see starting page 25 of the Form
10-K/A); Part&nbsp;II, Item&nbsp;7, captioned &#147;<I>Management&#146;s Discussion and Analysis of Results of Operations
and Financial Condition</I>&#148; (see starting page 28 of the Form 10-K/A); and Part&nbsp;II, Item&nbsp;8, captioned
&#147;<I>Financial Statements and Supplementary Data</I>&#148; (see starting page 45 of the Form 10-K/A).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Because the Company has already filed the Form&nbsp;10-K/A and its Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2010,
each of which addresses the issues raised in, and contain the disclosures requested by, this comment, the Company respectfully requests that it not be required
to amend its&nbsp;Form&nbsp;8-K, as the Company believes that amending its&nbsp;Form&nbsp;8-K to contain duplicative disclosures that are already on file
with the Commission may create confusion in the market.
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Please tell us whether you have reconsidered, in accordance with Item&nbsp;307 of
Regulation&nbsp;S-K, the adequacy of your previous assertions in your December&nbsp;31, 2009 10-K
filing regarding your disclosure controls and procedures, in light of the material error
that you have described.</U></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Response: </I>The Company acknowledges the Commission&#146;s comment and respectfully
refers the Commission to the Company&#146;s response to comment 1 above.
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Please tell us whether you have reassessed and whether you are planning to revise
your conclusion related to the effectiveness of your internal control over financial
reporting. Tell us whether your original disclosures are still appropriate or whether they
will be modified or supplemented to include any other material information that is
necessary for such disclosures not to be misleading in light of the restatement</U>.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Response: </I>The Company acknowledges the Commission&#146;s comment and respectfully
refers the Commission to the Company&#146;s response to comment 1 above.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">* * *
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Please call Todd Mason at (212)&nbsp;692-6731 or the undersigned at (212)&nbsp;692-6774 with any
comments or questions regarding this letter and please send a copy of any written comments to the
following parties:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 30%"><B>Joel I. Papernik, Esq.<BR>
Todd E. Mason, Esq.</B><BR>
Mintz, Levin, Cohn, Ferris,Glovsky and Popeo, P.C.<BR>
666 Third Avenue<BR>
New York, NY 10017<BR>
Fax: (212)&nbsp;983-3115

</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours,<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/Joel I. Papernik
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Joel I. Papernik&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">cc:</TD>
    <TD>&nbsp;</TD>
    <TD><U>Securities and Exchange Commission</U> (Tabitha Akins, Staff Accountant,
Division of Corporation Finance)<BR>
<U>Cyclacel Pharmaceuticals, Inc.</U> (Messrs.&nbsp;Spiro Rombotis and Paul McBarron)</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
